The story of copyright's flagship drug presents a complex case for stakeholders in the drug sector. While initially a blockbuster success, creating billions, the exclusivity expiration and the subsequent flood of off-brand alternatives have considerably impacted revenue. This poses questions about the future viability of similar drug innovations an